Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AB598 · 1 trial · 12 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Cohort 1 | EXPERIMENTAL | Participants will receive AB598 intravenous (IV) infusion once every 3 weeks |
| Dose Escalation Cohort 2 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Dose Escalation Cohort 3 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Dose Escalation Cohort 4 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Pharmacodynamic Cohort 1 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Pharmacodynamic Cohort 2 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Pharmacodynamic Cohort 3 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Dose Expansion Gastric/GEJ Cancer (phase 1b) | EXPERIMENTAL | Participants will receive AB598 IV infusion every 2 weeks in combination with zimberelimab and FOLFOX (oxaliplatin, leucovorin, fluorouracil) |
| Name | Type | Description |
|---|---|---|
| AB598 | DRUG | Administered as specified in the treatment arm |
| Zimberelimab | DRUG | Administered as specified in the treatment arm |
| Fluorouracil | DRUG | Administered as specified in the treatment arm |
| Leucovorin | DRUG | Administered as specified in the treatment arm |
| Oxaliplatin | DRUG | Administered as specified in the treatment arm |
Key Inclusion Criteria: * Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) guidance * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * Prior systemic radiation or whole brain radiation therapy must have been completed at ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AB598 is an investigational small molecule being studied for the treatment of advanced cancers, including bladder, cervical, esophageal, gastric, gastroesophageal-junction, head and neck squamous cell carcinoma, non-small cell lung, ovarian, renal cell, and triple negative breast cancer. It is currently in Phase 1 clinical development.
AB598 is being developed by Arcus Biosciences, Inc. (NYSE: RCUS). The company is conducting a Phase 1 clinical trial of AB598 as a monotherapy and in combination with other agents for the treatment of advanced cancers.
AB598 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 study is evaluating the safety and tolerability of AB598 in participants with advanced malignancies.
AB598 is being studied in a Phase 1 clinical trial with the identifier NCT05891171. This trial is titled "Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers" and is currently active but not recruiting participants.
Yes, the Phase 1 clinical trial of AB598 is designed to evaluate AB598 both as a monotherapy and in combination therapy. The study is enrolling participants with various advanced solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and triple negative breast cancer.